

TRACK 1: PRESCRIBER EDUCATION AND GUIDELINES - STATUS REPORT

Provided as a Reference to the Governor's Opioid State Action Accountability Taskforce.

Report Timeframe

From: 7/1/2018

To: 9/30/2018

Description

Track 1 focuses on education and guidelines for prescribers to reduce the risk of substance misuse and overdose. New prescribing requirements, established through AB 474 (2017 legislative session) went into effect January 1, 2018.

Highlights

- The State, through its licensing Boards and various agencies, worked with the public and prescribers to promulgate regulations to clarify AB 474.
- Support for prescriber questions and clarifications continue, but have slowed considerably in recent months, suggesting that the majority of prescribers have been able to access information about AB 474.
- The Board of Pharmacy is working with other partners to integrate the PMP (Prescription Monitoring Program, also referred to as PDMP) with other electronic data used by providers. This system change, when developed, will streamline access to information for physicians and other prescribers.
- There has been a significant increase in PMP registrations.

Milestones Completed

- All licensing boards have regulations in place in alignment with AB 474.
- The majority of the new regulations are now effective, with the final set pending approval by the Legislative Commission.
- The Board of Pharmacy in partnership with DHHS has developed an initial plan for PMP integration.
- Data from the PMP has been collected, analyzed, and shared.

Ongoing Action Items

- Collect, analyze, and share data from the PMP with key stakeholders
- Provide continuing education opportunities for providers of all disciplines regarding AB 474, the new regulations, and prescribing of controlled substances
- Continue to collaborate with licensing boards to review and, where appropriate, investigate concerns regarding inappropriate prescribing
- Work across sectors with the public and prescribers to promulgate regulations to clarify AB 474

Milestones Anticipated in the Next Quarter

Description of Milestone	Progress
1) Secure funding for the proposed integration project	In progress
2) Enter into a contract with a vendor for integration	In progress
3) Identify policies needed to enhance current laws	In progress

Challenges and Recommendations

To support ongoing improvement, challenges that were identified in quarter 4 are shared along with suggested actions.

The need for two-way communication regarding AB 474 with providers and the general public may be ongoing. Suggested Actions:

- Continue to promote and share information and resources developed in 2017 and 2018
- Use data from year 1 of implementation to strengthen support
- Identify if any additional actions are needed to meet the intended outcomes of the bill

Resources/Information

About AB 474 <https://www.youtube.com/watch?v=JvGB7QBACiM&feature=youtu.be>

Know Your Pain Meds <http://knowyourpainmeds.com/prescription-monitoring/>

Project ECHO Pain Management Resources <https://med.unr.edu/echo/clinics/pain-management>

Prescribe 365 Nevada (DPBH) <http://prescribe365.nv.gov/>

Nevada State Medical Association AB 474 Toolkit <https://nvdoctors.org/practice-resources/prescribing-opioids/>

Nevada Medical Association <https://nvdoctors.org/practice-resources/prescribing-opioids/>

Track 1 Contacts

Nevada Board of Pharmacy

Dave Wuest, Deputy Secretary
Nevada Board of Pharmacy
dwuest@pharmacy.nv.gov

S. Paul Edwards

General Counsel
Nevada Board of Pharmacy
pedwards@pharmacy.nv.gov